Ontology highlight
ABSTRACT: Objectives
To synthesise current evidence for the effects of exenatide and liraglutide on heart rate, blood pressure and body weight.Design
Meta-analysis of available data from randomised controlled trials comparing Glucagon-like peptide-1 (GLP-1) analogues with placebo, active antidiabetic drug therapy or lifestyle intervention.Participants
Patients with type 2 diabetes.Outcome measures
Weighted mean differences between trial arms for changes in heart rate, blood pressure and body weight, after a minimum of 12-week follow-up.Results
32 trials were included. Overall, GLP-1 agonists increased the heart rate by 1.86 beats/min (bpm) (95% CI 0.85 to 2.87) versus placebo and 1.90 bpm (1.30 to 2.50) versus active control. This effect was more evident for liraglutide and exenatide long-acting release than for exenatide twice daily. GLP-1 agonists decreased systolic blood pressure by -1.79 mm Hg (-2.94 to -0.64) and -2.39 mm Hg (-3.35 to -1.42) compared to placebo and active control, respectively. Reduction in diastolic blood pressure failed to reach statistical significance (-0.54 mm Hg (-1.15 to 0.07) vs placebo and -0.50 mm Hg (-1.24 to 0.24) vs active control). Body weight decreased by -3.31 kg (-4.05 to -2.57) compared to active control, but by only -1.22 kg (-1.51 to -0.93) compared to placebo.Conclusions
GLP-1 analogues are associated with a small increase in heart rate and modest reductions in body weight and blood pressure. Mechanisms underlying the rise in heart rate require further investigation.
SUBMITTER: Robinson LE
PROVIDER: S-EPMC3563145 | biostudies-literature | 2013 Jan
REPOSITORIES: biostudies-literature
Robinson Louise E LE Holt Tim A TA Rees Karen K Randeva Harpal S HS O'Hare Joseph P JP
BMJ open 20130124 1
<h4>Objectives</h4>To synthesise current evidence for the effects of exenatide and liraglutide on heart rate, blood pressure and body weight.<h4>Design</h4>Meta-analysis of available data from randomised controlled trials comparing Glucagon-like peptide-1 (GLP-1) analogues with placebo, active antidiabetic drug therapy or lifestyle intervention.<h4>Participants</h4>Patients with type 2 diabetes.<h4>Outcome measures</h4>Weighted mean differences between trial arms for changes in heart rate, blood ...[more]